This is perhaps best illustrated by the example of chronic myelogenous leukemia (CML), a disease driven by the BCR-ABL oncoprotein common to virtually all patients and sensitive to Gleevec, an inhibitor of BCR-ABL [2].
However, the incidence of the principal groups of cancers differs according to the country in which the study took place: For example, in the USA, the incidence of leukemia is 47.8 per 1,000,000 children/year [ 4], whereas in some countries, it can reach as high as 57.9 per 1,000,000 children/year [ 11].
Joseph Cortright, an economist who has studied biotechnology clusters, gave the example of a promising anti-leukemia compound developed at Oregon Health Sciences University in Portland, where Mr. Cortright is based.
The study also showed drops in rates of several cancers that, while not specifically considered markers of AIDS, are associated with viral causation (for example, melanoma, leukemia and cancer of the lung or larynx).
Some 3 to 5% of all newly diagnosed cancers are CUPs, which qualifies this disease entity as one of the ten most common cancer types, with an incidence that is greater than that of, for example, leukemia or pancreatic cancers [ 1, 2].
An example of comparing four drugs in the treatment of leukemia is given to demonstrate the proposed procedures.
An example of comparing four drugs in the treatment of leukemia is given to demonstrate the proposed methodology.
For example, the Seed Finding model is solved in 0.063 seconds for classification of leukemia.
For example, childhood cancer, of which the most common is a form of leukemia, has a simpler genetic profile than adult cancers.
However, it appears that DDX4 is so far the only example of a germline spliceosomal mutation in leukemia.
